Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05691153
Other study ID # SZ5602
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 1, 2022
Est. completion date November 30, 2025

Study information

Verified date December 2022
Source The First Affiliated Hospital of Soochow University
Contact Jia Chen, M.D., Ph.D.
Phone +86-512-67781856
Email drchenjia@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.


Description:

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma. The study will identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile. Before initiating ThisCART19A infusion, subjects will be administered lymphodepletion chemotherapy composed of fludarabine、cyclophosphamide and VP-16. At Day 0 of the Treatment Period, subjects will receive an intravenous (IV) infusion of ThisCART19A. All subjects are monitored during the treatment period through Day 28. All subjects who receive a dose of ThisCART19A will be followed up to 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date November 30, 2025
Est. primary completion date November 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Voluntarily sign a documented IRB-approved ICF prior to any screening procedure; 2. Gender not restricted, 18 years = age = 75 years; 3. Subjects with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma; 4. Life expectancy = 12 weeks at the time of enrollment; 5. Eastern Cooperative Oncology Group performance status score of 0 or 1; 6. At least one measurable lesion to be assessed, with any nodal lesion > 15mm in LDi (longest diameter) and any extranodal lesion > 10mm in LDi; 7. Subject has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as: 1. Adequate marrow function for lymphodepletion chemotherapy: 14 days before enrollment, absolute neutrophil count (ANC) = 1×10^9/L, platelet count = 30×10^9/L, hemoglobin = 80 g/L without blood transfusion; 2. Creatinine clearance = 30 ml/min according to the Cockcroft-Gault formula, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5 × the upper limit of normal (ULN), total bilirubin = 2×ULN (Subjects with Gilbert syndrome or liver involvement may be enrolled if their total bilirubin is = 3×ULN); 3. Pulmonary function: Baseline oxygen saturation (SaO2) = 92% on room air; 4. Cardiac function:left ventricular ejection fraction (LVEF) = 40% assessed by echocardiography. 8. CD19-positive lymphoma confirmed on a biopsy during screening. Exclusion Criteria: 1. Allergic to preconditioning measures in the trial. 2. Other malignancies apart from B-cell malignancies within 5 years prior to screening. (Subjects with cured skin squamous carcinoma, basal carcinoma, non-primary invasive bladder cancer, localized low-risk prostate cancer, in situ cervical/breast cancer can be recruited.) 3. Severe active infection (Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted). 4. Pulmonary embolism (PE) within 3 months prior to enrollment. 5. Intolerant severe cardiovascular and cerebrovascular diseases and hereditary diseases assessed by the investigator prior to enrollment. 6. Gastrointestinal involvement at risk of active bleeding. 7. Massive pericardial effusion, symptomatic thoracic or abdominal effusion. 8. Presence of CNS involvement (both primary and secondary) at screening confirmed by imaging or CSF testing. 9. Active hepatitis B virus (serum HBV-DNA = 2000 IU/mL), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or active syphilis infection prior to enrollment. (Patients with HBV-DNA < 2000 IU/mL can be enrolled, but should be administered antiviral drugs such as entecavir and tenofovir with relative clinical indicators monitored simultaneously during the treatment.) 10. Less than 100 days after allogeneic hematopoietic stem cell transplantation. 11. Vaccinated with influenza vaccine within 2 weeks prior to lymphodepletion chemotherapy. (Patients vaccinated with SARS-COV19 vaccine or inactivated; live/non-live adjuvant vaccines can be enrolled.) 12. Under treatment for graft versus host disease (GvHD). (GvHD cured subjects who had stopped immunosuppressive drugs for at least 1 month can be enrolled.) 13. Female subjects who are pregnant, breastfeeding or planning for pregnancy within 1 year after CAR-T cell infusion, or male subjects whose partners are planning for pregnancy within 1 year after CAR-T cell infusion; 14. Any conditions that would, in the investigator's assessment, increase risks in patients or interfere with the outcomes of the trial.

Study Design


Intervention

Drug:
ThisCART19A with Dose Level 1
ThisCART19A,2×10^6 cells/kg(Single dose of Allogeneic Anti-CD19 CAR T cells will be infused), after the lymphodepletion conditioning of fludarabine, CTX and VP-16
ThisCART19A with Dose Level 2
ThisCART19A,3×10^6 cells/kg(Single dose of Allogeneic Anti-CD19 CAR T cells will be infused), after the lymphodepletion conditioning of fludarabine, CTX and VP-16

Locations

Country Name City State
China The First Affiliated Hospital of Soochow University Suzhou Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University Fundamenta Therapeutics, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary BOR Best Overall Response Rate 3 month
Secondary ORR Objective response rate 2 year
Secondary CR Complete response rate 2 year
Secondary TTR Time to response 3 month
Secondary DOR Duration of response 2 year
Secondary EFS Event-free survival 2 year
Secondary PFS Progression-free survival 2 year
Secondary OS Overall survival 2 year
See also
  Status Clinical Trial Phase
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Withdrawn NCT02547948 - CD19-targeting CAR T Cells for B Cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03258047 - Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma Phase 2
Active, not recruiting NCT03478514 - Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Phase 2
Not yet recruiting NCT06058858 - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Recruiting NCT06415708 - Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma Phase 2
Active, not recruiting NCT03307746 - A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma Phase 1/Phase 2
Terminated NCT03670888 - A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients Phase 1
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting NCT06213311 - A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma Phase 2
Recruiting NCT04008251 - Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Phase 1
Recruiting NCT04637763 - CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Phase 1
Recruiting NCT04782193 - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03146533 - CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. Phase 1/Phase 2
Recruiting NCT05385263 - Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion Phase 2
Recruiting NCT03366324 - Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies Phase 1/Phase 2
Recruiting NCT03929107 - Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. Phase 2
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Recruiting NCT04289220 - Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia Phase 1